Want to see JP:9267 full AI Analyst Report?
Top Page
Genky DrugStores Co., Ltd.
(9267)
Select Model
Select Model
Rating:65Neutral
Price Target:
¥4,053.00
▲(7.51% Upside)
Action:Reiterated
Date:07/31/26
The score is driven primarily by solid financial performance (steady revenue growth, stable profitability, and improved leverage), partially offset by inconsistent free cash flow. Technicals are mixed (above key shorter/intermediate moving averages but below the 200-day), and valuation is fair on earnings but supported by a very low dividend yield.
Positive Factors
Consistent Revenue Growth
Sustained top-line expansion from 155B to 221B over 2022–2026 signals durable demand for Genky’s retail offering and execution in store-level sales. Persistent revenue growth supports capacity to reinvest in the store network and defend market share over the medium term.
Negative Factors
Volatile and Often Negative Free Cash Flow
Frequent negative free cash flow despite improving operating cash flow points to heavy reinvestment or timing issues, reducing the company’s ability to consistently fund debt repayment, dividends or buybacks from internal cash. This raises funding and liquidity risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Sustained top-line expansion from 155B to 221B over 2022–2026 signals durable demand for Genky’s retail offering and execution in store-level sales. Persistent revenue growth supports capacity to reinvest in the store network and defend market share over the medium term.
Read all positive factors
Genky DrugStores Co., Ltd. (9267) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥113.59B
Dividend Yield0.35%
Average Volume (3M)62.69K
Price to Earnings (P/E)14.5
Beta (1Y)0.69
Revenue Growth9.89%
EPS Growth11.20%
CountryJP
Employees1,841
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)258.51
Shares Outstanding31,042,568
10 Day Avg. Volume60,060
30 Day Avg. Volume62,690
Financial Highlights & Ratios
PEG Ratio1.17
Price to Book (P/B)1.68
Price to Sales (P/S)0.47
P/FCF Ratio-32.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)283.45
Revenue Forecast (FY)¥245.10B
Genky DrugStores Co., Ltd. Business Overview & Revenue Model
Company Description
Genky DrugStores Co., Ltd. engages in the management and operation of food and drug chain stores in Japan. Genky DrugStores Co., Ltd. was founded in 1988 and is headquartered in Sakai, Japan....
How the Company Makes Money
Genky DrugStores makes money primarily through retail sales to consumers in its drugstore locations. Its core revenue stream is the sale of merchandise across categories such as over-the-counter pharmaceuticals, health and personal care items, and...
Genky DrugStores Co., Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
56
Neutral
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 220.64B | 200.79B | 184.86B | 169.06B | 154.64B |
| Gross Profit | 44.92B | 35.09B | 32.53B | 29.90B | 26.68B |
| EBITDA | 18.12B | 16.41B | 14.47B | 11.73B | 10.73B |
| Net Income | 7.88B | 7.07B | 6.32B | 4.76B | 4.42B |
Balance Sheet | |||||
| Total Assets | 145.60B | 128.27B | 114.84B | 106.92B | 97.64B |
| Cash, Cash Equivalents and Short-Term Investments | 7.87B | 6.22B | 5.90B | 5.33B | 5.44B |
| Total Debt | 39.64B | 34.37B | 30.65B | 32.35B | 30.96B |
| Total Liabilities | 84.22B | 74.84B | 68.15B | 66.23B | 61.40B |
| Stockholders Equity | 61.37B | 53.43B | 46.68B | 40.68B | 36.23B |
Cash Flow | |||||
| Free Cash Flow | -3.13B | -2.50B | 2.98B | -1.12B | -4.39B |
| Operating Cash Flow | 16.98B | 12.60B | 13.26B | 8.77B | 6.08B |
| Investing Cash Flow | -20.28B | -15.62B | -10.63B | -9.74B | -10.59B |
| Financing Cash Flow | 4.95B | 3.35B | -2.06B | 854.00M | 2.04B |
Genky DrugStores Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ¥434.60B | 13.80 | 11.29% | 3.42% | 4.32% | 0.18% | |
67 Neutral | ¥536.06B | 16.02 | 10.75% | 1.20% | 12.20% | -25.42% | |
65 Neutral | ¥113.59B | 14.47 | ― | 0.34% | 9.89% | 11.20% | |
64 Neutral | ¥1.07T | 18.69 | 7.67% | 2.04% | ― | ― | |
64 Neutral | ¥512.94B | 15.97 | ― | 1.28% | 8.72% | 3.45% | |
54 Neutral | ¥392.50B | 23.18 | ― | 0.41% | 13.04% | -0.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:9267
Genky DrugStores Co., Ltd.
3,740.00
-965.00
-20.51%
JP:9989
Sundrug Co
3,712.00
-944.33
-20.28%
JP:7649
Sugi Holdings Co
2,714.50
-1,256.50
-31.64%
JP:3391
TSURUHA Holdings
2,404.50
160.40
7.15%
JP:3349
COSMOS Pharmaceutical Corporation
6,458.00
-2,894.39
-30.95%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
4,108.00
113.67
2.85%
Genky DrugStores Co., Ltd. Corporate Events
Genky DrugStores Boosts Revenue and Profit on Aggressive Store Expansion Despite Tax Headwinds
Jul 28, 2026
Genky DrugStores reported steady growth through the fiscal year ending June 2026, expanding its store network from 480 to 604 outlets and driving revenue to a forecast ¥244 billion, up 10.6% year on year, supported by higher same-store sales ...
Genky DrugStores Lifts Sales and Profit, Targets Further Growth in FY2027
Jul 28, 2026
Genky DrugStores reported solid growth for the fiscal year ended June 20, 2026, with net sales rising 9.9% to ¥220.6 billion and net income attributable to owners of the parent climbing 11.4% to ¥7.9 billion, supported by improved operat...
Genky DrugStores Posts July Sales Growth Driven by Store Expansion
Jul 28, 2026
Genky DrugStores reported that in July of the fiscal year ending June 2027, net sales across all stores rose 5.0% year on year, supported by a 5.0% annual increase in total store sales despite softer performance at existing outlets. Existing-store...
Genky DrugStores Extends Sales Growth as Store Network Expands
Jun 30, 2026
Genky DrugStores reported solid year-on-year growth for June 2026, with all-store net sales up 11.1% and existing-store sales rising 4.0%, driven mainly by higher customer traffic while spending per customer remained broadly flat. The company open...
Genky DrugStores Extends Sales Growth as Store Network Expands to 525 Locations
May 29, 2026
Genky DrugStores reported robust May performance for the fiscal year ending June 2026, with all-store net sales up 10.5% year on year and existing-store sales rising 2.9%. Customer traffic at existing stores increased 3.3%, while spending per cust...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.